Genmab Ending Development of Acasunlimab Cancer-Drug Candidate

Dow Jones2025-12-29

By Colin Kellaher

Genmab is pulling the plug on its acasunlimab cancer-drug candidate as part of a portfolio prioritization by the Danish biotechnology company.

Genmab on Monday said that while acasunlimab study data have been encouraging, the move reflects a thorough assessment of the evolving competitive landscape.

Genmab said it will focus its resources on the most value-creating opportunities in its late-stage portfolio, including Epkinly, petosemtamab and rinatabart sesutecan.

The company said its decision to scrap acasunlimab doesn't affect its full-year 2025 financial guidance.

Genmab in September struck a deal to buy cancer-treatment developer Merus for around $8 billion in cash.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 29, 2025 08:38 ET (13:38 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595733888?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-29 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595733888","market":"hk","top_or_hot":-1,"title":"Genmab Ending Development of Acasunlimab Cancer-Drug Candidate","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Genmab is pulling the plug on its acasunlimab cancer-drug candidate as part of a portfolio prioritization by the Danish biotechnology company. \n</p>\n<p>\n  Genmab on Monday said that while acasunlimab study data have been encouraging, the move reflects a thorough assessment of the evolving competitive landscape. \n</p>\n<p>\n  Genmab said it will focus its resources on the most value-creating opportunities in its late-stage portfolio, including Epkinly, petosemtamab and rinatabart sesutecan. \n</p>\n<p>\n  The company said its decision to scrap acasunlimab doesn't affect its full-year 2025 financial guidance. \n</p>\n<p>\n  Genmab in September struck a deal to buy cancer-treatment developer Merus for around $8 billion in cash. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 29, 2025 08:38 ET (13:38 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genmab Ending Development of Acasunlimab Cancer-Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenmab Ending Development of Acasunlimab Cancer-Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-29 21:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Genmab is pulling the plug on its acasunlimab cancer-drug candidate as part of a portfolio prioritization by the Danish biotechnology company. \n</p>\n<p>\n  Genmab on Monday said that while acasunlimab study data have been encouraging, the move reflects a thorough assessment of the evolving competitive landscape. \n</p>\n<p>\n  Genmab said it will focus its resources on the most value-creating opportunities in its late-stage portfolio, including Epkinly, petosemtamab and rinatabart sesutecan. \n</p>\n<p>\n  The company said its decision to scrap acasunlimab doesn't affect its full-year 2025 financial guidance. \n</p>\n<p>\n  Genmab in September struck a deal to buy cancer-treatment developer Merus for around $8 billion in cash. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 29, 2025 08:38 ET (13:38 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2595733888","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595733888","pubTimestamp":1767015480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Genmab is pulling the plug on its acasunlimab cancer-drug candidate as part of a portfolio prioritization by the Danish biotechnology company.Genmab on Monday said that while acasunlimab study data have been encouraging, the move reflects a thorough assessment of the evolving competitive landscape.Genmab said it will focus its resources on the most value-creating opportunities in its late-stage portfolio, including Epkinly, petosemtamab and rinatabart sesutecan.The company said its decision to scrap acasunlimab doesn't affect its full-year 2025 financial guidance.Genmab in September struck a deal to buy cancer-treatment developer Merus for around $8 billion in cash.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GMAB":"Genmab A/S"},"translate_title":"Genmab终止Acasunlimab癌症候选药物的开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMAB":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Genmab is pulling the plug on its acasunlimab cancer-drug candidate as part of a portfolio prioritization by the Danish biotechnology company. \n\n\n  Genmab on Monday said that while acasunlimab study data have been encouraging, the move reflects a thorough assessment of the evolving competitive landscape. \n\n\n  Genmab said it will focus its resources on the most value-creating opportunities in its late-stage portfolio, including Epkinly, petosemtamab and rinatabart sesutecan. \n\n\n  The company said its decision to scrap acasunlimab doesn't affect its full-year 2025 financial guidance. \n\n\n  Genmab in September struck a deal to buy cancer-treatment developer Merus for around $8 billion in cash. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 29, 2025 08:38 ET (13:38 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595733888","isCrawlerRequest":true}